The Oncologist, Vol. 11, No. 4, 420, April 2006; doi:10.1634/theoncologist.11-4-420
© 2006 AlphaMed Press
Errata
Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience
Ian Quirt, Michael Kovacs, Félix Couture, A. Robert Turner, Michael Noble, Ronald Burkes, Sean Dolan, Richard K. Plante, Catherine Y. Lau, José Chang
The Oncologist 2006; 11:73–82; doi: 10.1634/theoncologist.11-1-73
In Figure 3
, RR was incorrectly labeled as "response rate" when it should have been called out as "relative risk." Here we reprint the figure in its entirety. A corrected figure has been posted on http://www.TheOncologist.com.
View larger version (23K):
[in this window]
[in a new window]
|
Figure 3. Relative risk of subsequent transfusion was calculated as a function of baseline Hb strata relative to baseline Hb strata > 11 g/dl. (A): Relative risk of subsequent transfusion calculated in patients transfused after day 28 of epoetin alfa treatment. Patients initiating epoetin alfa therapy at a baseline Hb <10 g/dL had a RR of 2.65 (95% CI, 1.54–4.56) of receiving subsequent transfusions compared to patients initiating therapy earlier (Hb 10–11 g/dL). (B): Relative risk of subsequent transfusion calculated in patients transfused from baseline to end of study. Patients initiating epoetin alfa therapy at a baseline Hb <10 g/dL had a RR of 2.29 (95% CI, 1.54–3.42) of receiving subsequent transfusions compared to patients initiating therapy earlier (Hb 10–11 g/dL). Abbreviations: CI, confidence interval; Hb, hemoglobin; RR, Relative risk.
|
|
Figure 4 was incorrectly labeled. The upper line should be labeled "Baseline pre-transfusion" rather than "No baseline pretransfusion." Here we reprint the figure in its entirety. A corrected figure has been posted on http://www.TheOncologist.com.
View larger version (21K):
[in this window]
[in a new window]
|
Figure 4. Number of units of blood received by all patients and the subset of pretrans-fused patients during epoetin alfa treatment from day 1 to end of study as a linear function of baseline hemoglobin level.
|
|
It is regrettable that Fernando Camacho, Ph.D., statistician, was not included as a coauthor. His contributions and input in establishing the per-patient database and carrying out the statistical analyses were, unfortunately and inadvertently, not acknowledged in the original manuscript. Dr. Fernando Camacho should correctly have been listed as a coauthor on the manuscript published in The Oncologist. The online version has been corrected in departure from print.
